Home Biosimilar Antibodies Immunology & Inflammation CD markers Tisotumab (Anti-Tissue factor / CD142)
For research use only. Not for use in humans.

Tisotumab (Anti-Tissue factor / CD142)

Synonyms: F3,CD142

Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD.

Tisotumab (Anti-Tissue factor / CD142)

Quality Control

Batch: Purity: 99% Protein concentration: 10.751mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD.

Product Details

CAS No. 1418628-81-5
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07434609 NOT_YET_RECRUITING Advanced Solid Tumor (Phase 1) Nanolattix Biotechnology Co., Ltd. 2027-12-01 PHASE1
NCT07672782 NOT_YET_RECRUITING Drug: Tisotumab Vedotin Vulvar Carcinoma; Recurrent or Metastatic Vulvar Cancer; Squamous Cell Carcinoma Vulva GOG Foundation 2026-11 PHASE2
NCT06459180 ACTIVE_NOT_RECRUITING Drug: Pemetrexed|Drug: Topotecan|Drug: Vinorelbine|Drug: Gem Cervical Cancer Merck Sharp & Dohme LLC 2024-07-24 PHASE3
NCT03485209 ACTIVE_NOT_RECRUITING Drug: tisotumab vedotin|Drug: pembrolizumab|Drug: carboplati Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Exocrine Pancreatic Cancer; Carcinoma, Squamous Cell of Head and Neck Seagen, a wholly owned subsidiary of Pfizer 2018-06-25 PHASE2
NCT03786081 TERMINATED Drug: Tisotumab Vedotin|Drug: Bevacizumab|Drug: Pembrolizuma Cervical Cancer Seagen, a wholly owned subsidiary of Pfizer 2019-02-27 PHASE1; PHASE2
NCT05866354 COMPLETED Drug: Tisotumab Vedotin Solid Malignancies Zai Lab (Shanghai) Co., Ltd. 2023-06-16 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-02-25)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.